|
| Combined knockdown or dual-inhibition of BRD4 and CBP/p300 down-regulated CUB domain-containing protein 1 (CDCP1) transcription and downstream PI3K/AKT and/or SRC/MAPK signaling pathways in CRPC cells much more so than single-protein perturbation.
[Oncogene] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The secretome of CRPC cells mediated neo-angiogenesis in an androgen-dependent manner, which was counteracted by atraric acid.
[Oncogene] |
|
|
|
| Transcriptional heterogeneity was analyzed in pools of ten DU145 and PC3 cells with multiplex gene expression analyses and illustrated a higher degree of heterogeneity within the aldehyde dehydrogenase-positive (ALDH+) population that even increased upon irradiation in comparison with ALDH− cells.
[Molecular Cancer Research] |
|
|
|
| Stimulation of arginine vasopressin receptor type 2 (AVPR2) with a selective agonist desmopressin promoted CRPC cell proliferation through cAMP/protein kinase A signaling, consistent with AVPR2 coupling to the G alpha s subunit.
[Molecular Cancer Research] |
|
|
|
| Researchers determined whether the non-drug efflux function of ATP binding cassette subfamily C member 5 (ABCC5) affected enzalutamide resistance. The ABCC5 expression data in patients with prostate cancer were retrieved from The Cancer Genome Atlas and Gene Expression Omnibus.
[Cell Death Discovery] |
|
|
|
| Scientists analyzed and demonstrated that two enantiomers of naftopidil, an α1D/1A-adrenoceptor blocker, induced expression and activity of UDP-glucuronosyltransferase 2B (UGT2B) in benign prostate hyperplasia rat prostate models as well as UGT2B15 in human prostate cells, BPH-1.
[Journal of Steroid Biochemistry and Molecular Biology] |
|
|
|
| Cellular proliferation, qPCR, Western blot and apoptosis assays were performed to investigate the molecular mechanism of selected miRNAs in the prostate cancer cells.
[Life Sciences] |
|
|
|
| The authors showed that the combination of tetracyclic aromatic core and docetaxel had strong synergism in inhibiting prostate cancer cell survival.
[Bioorganic & Medicinal Chemistry] |
|
|
|
| A 2RRV1 mouse xenograft model was established to detect the effect of SBD on prostate cancer (PCa). Angiogenesis was analyzed by coculturing PCa cell lines and human umbilical vein endothelial cells.
[BMC Complementary and Alternative Medicine] |
|
|
|
|
| The authors summarize the challenges targeting the tumor environments, and emphasize that continued exploration of tumor heterogeneity is needed in order to offer a personalized therapy for advanced prostate cancer patients.
[npj Precision Oncology] |
|
|
|
| Scientists review the potential etiologies of cognitive decline in patients with prostate cancer, including the potential role of androgen receptor pathway inhibitors.
[CNS Drugs] |
|
|
|
|
| Bayer announced the US FDA has accepted a sNDA and granted Priority Review for the oral androgen receptor inhibitor darolutamide in combination with docetaxel for the treatment of mHSPC.
[Bayer AG] |
|
|
|
|
|
|
|
| | Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
| | Oslo University Hospital – Oslo, Norway |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | University Hospital Frankfurt – Frankfurt, Germany |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
